498 related articles for article (PubMed ID: 9262379)
21. Synthesis of the butanamide derivative S 19812, a new dual inhibitor of cyclooxygenase and lipoxygenase pathways.
Tordjman C; Sauveur F; Droual M; Briss S; Andre N; Bellot I; Deschamps C; Wierzbicki M
Arzneimittelforschung; 2003; 53(11):774-9. PubMed ID: 14677373
[TBL] [Abstract][Full Text] [Related]
22. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
Masferrer JL; Zweifel BS; Hardy M; Anderson GD; Dufield D; Cortes-Burgos L; Pufahl RA; Graneto M
J Pharmacol Exp Ther; 2010 Jul; 334(1):294-301. PubMed ID: 20378715
[TBL] [Abstract][Full Text] [Related]
23. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase.
Li L; Zeng H; Shan L; Yuan X; Li Y; Liu R; Zhang W
J Ethnopharmacol; 2012 Sep; 143(2):732-9. PubMed ID: 22884869
[TBL] [Abstract][Full Text] [Related]
24. Effect of combination of misoprostol and indomethacin on eicosanoid production in carrageenan-induced air pouch inflammation in rats.
Sayar K; Melli M
Eur J Pharmacol; 1999 Mar; 369(3):365-71. PubMed ID: 10225376
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989.
Spaethe SM; Hsueh W; Needleman P
J Pharmacol Exp Ther; 1989 Mar; 248(3):1308-16. PubMed ID: 2539462
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
Hanna N; Marshall PJ; Newton J; Schwartz L; Kirsh R; Dimartino MJ; Adams J; Bender P; Griswold DE
Drugs Exp Clin Res; 1990; 16(4):137-47. PubMed ID: 2127565
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of 5-lipoxygenase/cyclooxygenase by a reconstituted homeopathic remedy; possible explanation for clinical efficacy and favourable gastrointestinal tolerability.
Jäggi R; Würgler U; Grandjean F; Weiser M
Inflamm Res; 2004 Apr; 53(4):150-7. PubMed ID: 15060721
[TBL] [Abstract][Full Text] [Related]
28. Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase.
Araico A; Terencio MC; Alcaraz MJ; Domínguez JN; León C; Ferrándiz ML
Life Sci; 2006 May; 78(25):2911-8. PubMed ID: 16360707
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
31. [The yin yang of inflammation: inducible and constitutive cyclooxygenase. Nimesulide and selective inhibitors of inducible cyclooxygenase].
Cirino G; Coppini A; Bigini C; Mitchell JA
Eur Rev Med Pharmacol Sci; 1998; 2(3 Suppl 1):1-8. PubMed ID: 10887524
[No Abstract] [Full Text] [Related]
32. Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition.
Geronikaki AA; Lagunin AA; Hadjipavlou-Litina DI; Eleftheriou PT; Filimonov DA; Poroikov VV; Alam I; Saxena AK
J Med Chem; 2008 Mar; 51(6):1601-9. PubMed ID: 18311898
[TBL] [Abstract][Full Text] [Related]
33. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.
Lesch CA; Gilbertsen RB; Song Y; Dyer RD; Schrier D; Kraus ER; Sanchez B; Guglietta A
J Pharmacol Exp Ther; 1998 Oct; 287(1):301-6. PubMed ID: 9765350
[TBL] [Abstract][Full Text] [Related]
34. A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor.
Farina PR; Graham AG; Homon CA; Lazer ES; Hattox SE; Riska PS; Gundel RH; Wegner CD
J Pharmacol Exp Ther; 1993 May; 265(2):483-9. PubMed ID: 8388452
[TBL] [Abstract][Full Text] [Related]
35. Effects of selective inhibition of cyclooxygenase and lipooxygenase pathways in follicle rupture and ovulation in the rat.
Gaytán M; Bellido C; Morales C; Sánchez-Criado JE; Gaytán F
Reproduction; 2006 Oct; 132(4):571-7. PubMed ID: 17008468
[TBL] [Abstract][Full Text] [Related]
36. [Nimesulide - a non-steroidal anti-inflammatory drug, a preferential cyclooxygenase-2 inhibitor].
Bennett A; Vila D
Vutr Boles; 2000; 32(1):33-6. PubMed ID: 11195195
[TBL] [Abstract][Full Text] [Related]
37. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man.
Depré M; Van Hecken A; Verbesselt R; Verpooten GA; Arnout J; Brunner F; Jurgens A; Pousset V; Chow A; Baldauf C; Vermylen J; De Broe M; De Schepper PJ
Int J Clin Pharmacol Res; 1996; 16(1):1-8. PubMed ID: 9001924
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
39. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
40. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors.
de Gaetano G; Donati MB; Cerletti C
Trends Pharmacol Sci; 2003 May; 24(5):245-52. PubMed ID: 12767724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
